Cariprazine: A Review in Schizophrenia

@article{Garnockjones2017CariprazineAR,
  title={Cariprazine: A Review in Schizophrenia},
  author={Karly P Garnock-jones},
  journal={CNS Drugs},
  year={2017},
  volume={31},
  pages={513-525}
}
Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder. In 6-week, phase IIb and III trials in patients with schizophrenia, cariprazine was significantly more efficacious than placebo in improving schizophrenia symptoms, including improvements in Positive and… 

[Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study)].

Initial effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1-2 weeks of treatment is suggested and could be useful for determination of early clinical predictors for efficacy.

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series

It is suggested that cariprazine may be effective in the treatment of psychosis in a broader sense and should be considered a first-line treatment option.

Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases

Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments, however, further studies are needed to consubstantiate those findings.

Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series

A case series supports cariprazine as an effective treatment for positive and negative symptoms in patients who failed to adequately respond or poorly tolerated treatment with clozapine, as well as a potential treatment in dual disorders, specifically psychotic disorders and cocaine use disorder.

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

Early effect of cariprazine on negative symptoms at least in some schizophrenia patients with predominantly negative symptoms starting from 1 to 2 weeks of treatment is suggested and could be useful for determination of early clinical predictors for efficacy.

Brexpiprazole: A Review in Schizophrenia

Brexpiprazole was generally well tolerated, exhibiting an adverse event profile characterized by a relatively low incidence of activating and sedating adverse effects, small changes in QT interval and metabolic parameters that were not clinically significant, and moderate weight gain.

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms

  • O. Vasiliu
  • Psychology, Medicine
    Frontiers in Psychiatry
  • 2021
After 12 weeks of cariprazine 6 mg/day, the positive scale of PANSS was relatively stable compared to baseline, while the negative mean score decreased by 22%.

NDT_A_343747 1145..1149

Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments.

New drugs in psychiatry-cariprazine, lurasidone, esketamine

The action profile of these drugs, the research to date and the results of treatment with these drugs are very promising and it is clinical practice that will verify the usefulness and effectiveness oftreatment with them and show the effects of long-term therapies with their use.

References

SHOWING 1-10 OF 39 REFERENCES

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

  • L. Citrome
  • Psychology, Medicine
    Advances in Therapy
  • 2013
In short-term, randomized controlled trials, cariprazine does not appear to adversely impact metabolic variables, prolactin, or the electrocardiogram (ECG) QT interval, and the most commonly encountered adverse events were insomnia, extrapyramidal disorder, sedation, akathisia, nausea, dizziness, vomiting, anxiety, and constipation.

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial

It is suggested that cariprazine may be a new and effective treatment for schizophrenia with significant improvement on primary and secondary efficacy parameters.

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

Once-daily cariprazine was generally well tolerated in adult patients with schizophrenia, and exposure was dose proportional over the range of 3–9 mg/day.

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study

Long-term cariprazine treatment at doses up to 9 mg/d appeared to be generally safe and well tolerated in patients with schizophrenia.

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial

In this study, patients treated with low-dose cariprazine showed significantly greater improvement in schizophrenia symptoms relative to placebo-treated patients, and car iprazine was generally well tolerated.

P.3.d.025 Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data